Other

Accrued development costs

Neurocrine Biosciences Accrued development costs increased by 9.3% to $110.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 23.4%, from $89.70M to $110.70M. Over 3 years (FY 2022 to FY 2025), Accrued development costs shows an upward trend with a 37.3% CAGR.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ4 2022
Last reportedQ1 2026May 5, 2026
Metric ID: other_accrued_research_and_development_expense_current

Historical Data

12 periods
 Q4 '22Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$39.10M$39.50M$44.30M$41.30M$34.70M$38.30M$50.80M$89.70M$61.00M$82.40M$101.30M$110.70M
QoQ Change—+1.0%+12.2%-6.8%-16.0%+10.4%+32.6%+76.6%-32.0%+35.1%+22.9%+9.3%
YoY Change——+13.3%——-3.0%+14.7%+117.2%+75.8%+115.1%+99.4%+23.4%
Range$34.70M – $110.70M
CAGR+46.0%
Avg YoY Growth+57.0%
Median YoY Growth+49.6%
Current Streak3 quarters growth

Frequently Asked Questions

What is Neurocrine Biosciences's accrued development costs?
Neurocrine Biosciences (NBIX) reported accrued development costs of $110.70M in Q1 2026.
How has Neurocrine Biosciences's accrued development costs changed year-over-year?
Neurocrine Biosciences's accrued development costs increased by 23.4% year-over-year, from $89.70M to $110.70M.
What is the long-term trend for Neurocrine Biosciences's accrued development costs?
Over 3 years (2022 to 2025), Neurocrine Biosciences's accrued development costs has grown at a 37.3% compound annual growth rate (CAGR), from $39.10M to $101.30M.